Researchers at Washington University School of Medicine in St. Louis report that a blood test originally developed to track toxic tau protein clumps in Alzheimer's disease also picks up signs of advanced chronic traumatic encephalopathy, or CTE. The study was published November 13 in JAMA. CTE is a degenerative brain disease linked to repeated blows to the head, and at present it can only be confirmed by examining the brain after death.
The biomarker in question is a tau fragment called eMTBR-tau243. The team, led by Horie and co-senior author Chihiro Sato, PhD, along with co-author Randall J. Bateman, MD, first wanted to know whether this marker was specific to Alzheimer's or shared by other tauopathies, the group of diseases driven by tau buildup. Both Alzheimer's and CTE involve clumps of tau in which both forms of the protein accumulate, which is why the researchers suspected overlap.
The work began with samples from more than 80 people with brain diseases confirmed at autopsy, along with healthy volunteers. Levels were very high in Alzheimer's and low in diseases where only one tau form clumps. One patient stood out: an autopsy showed no Alzheimer's but the blood level was unexpectedly high, and the records revealed advanced CTE. Blood from 11 people with autopsy-confirmed CTE then showed levels above those of healthy people, rising with disease severity.
The test separated people with advanced CTE from healthy people with high accuracy, but it could not reliably identify early-stage CTE, and CTE levels were much lower than those seen in Alzheimer's. The authors stress that the marker cannot distinguish the two conditions on its own, which matters because the diseases often occur together. Sato put it this way: "This is not going to be a standalone biomarker." Her suggested scenario is a person with repeated head injury who tests negative for Alzheimer's but shows an elevated result, which might point toward CTE.
For caregivers and researchers, the appeal is practical. Many companies are developing drugs that could treat CTE, but there has been no way to identify the disease in living people or to tell quickly whether a treatment is working. A validated blood test could help monitor groups the authors name as at risk, including former football players, boxers and combat veterans, and could make drug trials possible. The technology is licensed to C2N Diagnostics, which has an FDA-cleared Alzheimer's blood test, but the study authors note that the current test has not been validated for diagnosing CTE, and larger studies are needed before any clinical use. The study included 229 participants in total.